BRCA1 and cancer: In November 2020, the FDA approved the next-generation sequencing (NGS)-based FoundationOne Liquid CDx test that uses cf-DNA isolated from plasma of cancer patients for use in mCRPC to identify mutations on the BRCA1, BRCA2 and ATM genes [76].